Monday, 6 January 2020

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis - Yahoo Finance

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis  Yahoo Finance

from "phlebotomy" - Google News https://yhoo.it/39LbhNB

No comments:

Post a Comment